Portsmouth Naval Shipyard delivered USS Providence (SSN 719) 23 days ahead of schedule

PORTSMOUTH NAVAL SHIPYARD, Maine (NNS) — Portsmouth Naval Shipyard delivered USS Providence (SSN 719) back to the Fleet 23 days ahead of schedule and on budget April 7.

USS Providence arrived at Portsmouth Naval Shipyard Dec. 4, 2015, for a Pre-Inactivation Restricted Availability (PIRA). The project team and ship’s crew worked seamlessly throughout the maintenance availability to meet the Naval Sea Systems Command’s mission priority of the on-time delivery of ships and submarines.

As a team, the shipyard with the captain and crew of Providence, focused on the positive plan forward,” said project superintendent, Mark Ayotte. „Together we reached our goal of getting the warfighter underway to do what they do best for the Navy and our country.”

The project team and crew thrived in an environment that promotes increased levels of collaboration, innovation and high velocity learning. Their teamwork coupled with the shipyard’s collective commitment to excellence ensured non-stop execution of work.

„Portsmouth is committed to safely delivering first-time quality work, on time and on budget,” said shipyard commander, Navy Capt. Dave Hunt. „It is our commitment to safety and quality that enables us to deliver these submarines on or ahead of schedule and provide the combatant commanders with the assets they need, when they are needed.”

Providence’s PIRA was approximately 200,000 mandays of work scheduled for a 15.7 month time frame. The project team and crew completed the complex work package more than three weeks ahead of schedule.

The on-time completion of submarine availabilities is critical in the maintenance of today’s fleet and is essential to maintaining maritime superiority and expanding the advantage. PNSY, a field activity of NAVSEA, is the Navy’s center of excellence for attack submarine overhaul, repair and modernization.

For more information, visit www.navy.mil, , or .

For more news from Naval Sea Systems Command, visit www.navy.mil/local/navsea/.

Future USS Gerald R. Ford Underway for Builder’s Sea Trials

Department of the Navy's picture

Printer-friendly versionPrinter-friendly version

Story Number: NNS170408-02Release Date: 4/8/2017 5:17:00 PM

From Naval Sea Systems Command Public Affairs

WASHINGTON (NNS) — The future USS Gerald R. Ford (CVN 78) is underway for its first set of sea trials, known as Builder’s Sea Trials (BST). Builder’s sea trials provide an opportunity to test systems, components and compartments at sea for the first time.

Over the next several days, CVN 78 Sailors, shipbuilders from Huntington Ingalls Industries – Newport News Shipbuilding (HII-NNS), the Navy’s Supervisor of Shipbuilding and Naval Sea Systems Command personnel will be working side-by-side testing many of the ship’s key systems and technologies.

The Navy and our industry partners are excited to have the future USS Gerald R. Ford underway under her own power for the first time, executing a rigorous and comprehensive test program for this first-of-class ship,” said Rear Adm. Brian Antonio, program executive officer for aircraft carriers. „This milestone is the culmination of years of hard work and dedication, and we look forward to learning a great deal during sea trials. We will continue to work together to deliver Ford’s critical capabilities to the fleet.”

For more information, visit www.navy.mil, www.facebook.com/usnavy, or www.twitter.com/usnavy.

For more news from Naval Sea Systems Command, visit www.navy.mil/local/navsea/.

Copy this html code to your website/blog to embed this press release.

Navy Releases 2017 MAP Quotas, Policy Updates

WASHINGTON (NNS) — The Navy announced Tuesday in NAVADMIN 079/17 several changes to the 2017 Meritorious Advancement Program (MAP) that will expand commanding officers’ ability to recognize and advance top performing Sailors.

These changes are based on recommendations from senior enlisted leaders throughout the Fleet and will increase the number of quotas, eliminate the time-in-rate requirement and open MAP to Selected Reserve (SELRES) Sailors.

This year, MAP will account for approximately 10 percent of all E4-E6 advancements with 4,199 MAP quotas, an increase of more than 1,100 from 2016.

Units will have 4,016 quotas with 183 quotas designated for Echelon 2 commands. Advancement quotas by paygrade are:

* E-4 – 1,606

* E-5 – 1,354

* E-6 – 1,239

The 2017 fall advancement cycle planning will incorporate the number of Sailors advanced via MAP to arrive at quotas for advancement based on Navy Wide Advancement Exam results.

Some of the other key changes announced include:

* Increasing the number of Unit Identification Codes (UICs) receiving quotas from 907 to 2,798

* Time in Rate (TIR) requirements for E4 and E5 Sailors are eliminated

* Commanding Officers may MAP any Sailor in a subordinate UIC, regardless of their sea or shore assignment status

* MAP will be opened to Selected Reserve (SELRES) Sailors during this MAP Season. Policy, guidance and quota distribution for SELRES will be outline in a future ALNAVRESFOR message. Navy recruiting districts (NRD) will have one MAP quota per NRD for Reserve Sailors filling canvasser recruiter billets.

* Controlled rate quota requests must be submitted no later than June 1, 2017.

MAP open season will last from July 1 – Aug. 31, but commands are encouraged to begin the MAP selection process and submit their MAP Certification Letter (MCL) as early as possible. The redistribution of unused MAP quotas will take place during the month of September.

MAP is designed to give commanding officers greater authority to recognize superior performance and advance their very best Sailors.

For more information, including quotas by UIC, controlled rates information, forms, points of contact, and answers to frequently asked questions please read NAVADMIN 079/17 or visit http://www.public.navy.mil/bupers-npc/career/talentmanagement/Pages/MAP.aspx.

For more news from Chief of Naval Personnel, visit www.navy.mil/local/cnp/.

For more information, visit http://www.navy.mil, , or http://www.twitter.com/usnavy.

For more news from Chief of Naval Personnel, visit http://www.navy.mil/local/cnp/.

CNP Begins to Transform MPT&E and Charts Course for the Future

WASHINGTON (NNS) — Monday, the Chief of Naval Personnel announced that the Manpower, Personnel, Training and Education (MPT&E) organization is going to transform its processes and IT infrastructure to enhance the Navy’s ability to recruit, train and retain the force of tomorrow.

MPT&E is a dynamic organization and must constantly evolve as an organization in order to address both current and future challenges and maintain Fleet readiness,” said Chief of Naval Personnel Vice Adm. Robert Burke. „For us, that means we must be poised to quickly adapt our workforce to new and evolving threats while continuing to attract and retain the very best Sailors in a competitive talent market.”

Burke said that while the Navy is able to make the personnel machine work today, it comes at a cost in terms of resources and level of effort.

„Given the amount of technological change that has occurred in recent years, coupled with a pressurized fiscal environment, we believe the time is right to modernize our personnel management processes and IT infrastructure,” said Burke. „Incremental change will not be enough – we simply cannot afford to wait.”

This transformation effort is a holistic effort intended to streamline personnel management processes and dramatically improve quality of service to Sailors, Fleet Commanders and the Navy as a whole. As part of this effort, the MPT&E organization will transform its current IT architecture to a modern system with cloud based aspects as well as develop an integrated pay and personnel system for Sailors.

To benchmark these systems, the Navy has leveraged several fortune 500 companies to help shape its efforts and incorporated lessons learned from the Army’s on-going Integrated Pay and Personnel System development effort.

„Transforming the way MPT&E operates to streamline and optimize all of our processes will help us improve Fleet readiness, customer service to our Sailors, reduce operating costs and better manage our organizational data and programs,” said Burke. „It will also allow us to effectively recruit, train, and retain the force of tomorrow as well as strengthen the Navy for the future.”

MPT&E’s goals with this transformation are to:

* Improve Fleet Readiness – predictive analytics will enable better Sailor fit, talent matching, improved retention, and agile responses to meet dynamic Fleet needs

* Dramatically improve the way we support Sailors and their families

* Create call centers and mobile/online self-service portals for Sailors to access their personnel information, and provide 24/7 customer service where the majority of personnel transactions can be done online or via mobile devices like many banks and companies today

* Reduce cost without loss of output via a new operating model and modern IT system

* Transform labor intensive, antiquated processes into standardized, automated ones that require less management oversight

* Provide accurate, auditable and timely personnel and pay actions

* Have a seamless data environment accessible throughout the enterprise

* Enable predictive analytics supported by Big Data

A successful MPTE Transformation effort will result in significantly improved business processes and integrated personnel, learning, recruiting, pay, financial management, and data systems.

Once complete, Sailors will be able to upload documents such as marriage and birth certificates to their personnel files, have award and performance records in one place, see where their orders are in the release process, and have 24/7 customer service support through call centers and mobile applications. This effort will also help provide real time data to the Navy, which will help inform bonus-decisions, and potentially help the service move toward tailored compensation for Sailors.

The Navy plans to conduct a field test of its integrated pay and personnel system later this year at Recruit Training Command for approximately 1,000 recruits. The test will run in parallel with the Navy’s current personnel systems, which will provide a non-disruptive, side-by-side, comparison of personnel and pay transactions. While actual data will be employed in this parallel test, all actual pay and personnel actions will continue to be processed via current systems. Officer and Reserve elements will not be included in this first test.

Additionally, to help improve customer service and Fleet readiness, the Navy intends to internally reorganize MPT&E’s command structure later this year.

The Manpower, Personnel, Training and Education (MPT&E) enterprise is responsible for manning the Fleet and making sure that our Sailors are ready for the litany of jobs and tasks they will be asked to undertake in the Navy. This responsibility includes finding and recruiting talented individuals to serve, executing training pipelines that take young Sailors through their initial education and beyond, and ensuring that our ships, squadrons, and submarines are fully manned.

For more news from Chief of Naval Personnel, visit http://www.navy.mil/local/cnp/.

SAIC Announces Fourth Quarter and Full Fiscal Year 2017 Results

MCLEAN, Va.–(BUSINESS WIRE)–Science Applications International Corporation (NYSE: SAIC), a leading technology integrator providing full life cycle services and solutions in the technical, engineering, intelligence, and enterprise information technology markets, today announced results for the fourth quarter and full fiscal year ended February 3, 2017.

“SAIC’s fourth quarter and full fiscal year 2017 results demonstrate continued execution of the business strategy and although revenue growth was a challenge, we are positioned well against an improving market backdrop,” said SAIC CEO Tony Moraco. “Program performance, margin improvement, strong cash flow generation and disciplined capital deployment continue to be the hallmarks of the SAIC shareholder value proposition.”

 

Fourth Quarter and Full Fiscal Year 2017: Summary Operating Results

   
Three Months Ended Year Ended
   

February 3,
2017

 

Percent
change

 

January 29,
2016

 

February 3,
2017

 

Percent
change

 

January 29,
2016

    (in millions, except per share amounts)  
Revenues $ 1,026   (4 %)   $ 1,071 $ 4,450   3 %   $ 4,315
Operating income 61 13 % 54 271 19 % 227
Operating income as a percentage of revenues 5.9 % 90 bps 5.0 % 6.1 % 80 bps 5.3 %
Adjusted operating income(1) 61 (5 %) 64 281 11 % 253
Adjusted operating income as a percentage of revenues     5.9 %   -10 bps     6.0 %     6.3 %   40 bps     5.9 %
Net income     36     29 %     28       148     26 %     117  
EBITDA(1) 73 0 % 73 322 13 % 286
EBITDA as a percentage of revenues 7.1 % 30 bps 6.8 % 7.2 % 60 bps 6.6 %
Adjusted EBITDA(1) 73 (9 %) 80 330 7 % 309
Adjusted EBITDA as a percentage of revenues     7.1 %   -40 bps     7.5 %     7.4 %   20 bps     7.2 %
Diluted earnings per share $ 0.79 32 % $ 0.60 $ 3.22 30 % $ 2.47
Adjusted diluted earnings per share(1)   $ 0.79     7 %   $ 0.74     $ 3.35     18 %   $ 2.85  
Cash flows provided by operating activities $ 62 (43 %) $ 108 $ 273 21 % $ 226
Free cash flow(1)   $ 58     (41 %)   $ 99     $ 258     25 %   $ 206  
 

(1)

 

Non-GAAP measure, see Schedule 5 for information about this measure.

 

Revenues for the quarter decreased $45 million, or 4%, compared to the prior year primarily due to lower subcontractor activity within our AMCOM contract portfolio ($12 million), the re-compete loss of an IT integration program for the Department of Homeland Security ($8 million), customer driven delays on a Marine Corp IT services program ($12 million), various other decreases across our contract portfolio and one less productive day in the quarter ($17 million). These decreases were partially offset by revenues on newly awarded programs including the Amphibious Combat Vehicle (ACV) and GSA Enterprise Operations programs ($47 million).

Revenues for the fiscal year increased $135 million, or 3% compared to the prior year, primarily due to revenues earned on contracts obtained through the acquisition of Scitor (which occurred in the second quarter of the prior year period), revenues on newly awarded programs including the ACV and GSA Enterprise Operations programs ($138 million) and revenues due to one additional week in the current year period ($88 million). These increases were partially offset by lower activity on our supply chain and logistics services programs as the result of the loss of two contracts in the prior year ($75 million), the expected decline on the Assault Amphibious Vehicle program as we near completion of the prototyping phase ($25 million), and various other decreases across our contract portfolio due to programs that have ended or have experienced lower activity. Revenues from work performed jointly with our former parent company also decreased, as expected, as we complete pre-separation joint work ($22 million).

Operating income for the quarter increased $7 million to 5.9% of revenues, up from 5.0% for the prior year quarter. This increase was primarily due to lower acquisition and integration expenses ($10 million), lower intangible asset amortization ($5 million) and cost savings initiatives ($6 million). These increases were partially offset by higher bid and proposal (B&P) activity to address a strong pipeline of opportunities ($6 million), lease exit costs ($5 million) and lower revenue volume ($4 million).

Operating income for the fiscal year increased $44 million to 6.1% of revenues, up from $227 million, or 5.3% of revenues, in the prior fiscal year. The increase in operating income was primarily due to a decrease in acquisition and integration costs ($16 million), higher net favorable changes in estimates on contracts accounted for using the percentage-of-completion method ($9 million), cost savings initiatives ($10 million), lower intangible asset amortization ($8 million) and increased revenue volume ($12 million). These increases were partially offset by higher B&P activity ($9 million) and lease exit costs ($5 million).

Net income for the quarter increased $8 million from the comparable prior year period primarily due to increased operating income ($5 million, net of tax), lower effective tax rate ($1 million), higher other income ($1 million, net of tax), and lower interest expense primarily due to lower principal outstanding ($1 million, net of tax).

Net income for the fiscal year increased $31 million from the prior fiscal year primarily due to increased operating income ($28 million, net of tax) and a lower effective tax rate ($7 million), partially offset by increased interest expense primarily due to one additional quarter of interest in the current year on additional borrowings.

EBITDA(1) for the quarter increased to 7.1% of revenues, compared to EBITDA(1) of 6.8% for the comparable prior year quarter. The increase was primarily due to lower acquisition and integration expenses and cost savings initiatives, partially offset by higher B&P activity and lease exit costs.

EBITDA(1) for the fiscal year increased to 7.2% of revenues, compared to EBITDA(1) of 6.6% in the prior fiscal year. The increase was primarily due to an increase in net favorable changes in estimates on contracts accounted for under the percentage-of-completion method, cost savings initiatives, and lower costs related to the acquisition and integration of Scitor.

Diluted earnings per share was $0.79 for the quarter. The weighted-average diluted shares outstanding during the quarter was 45.3 million shares. Diluted earnings per share was $3.22 for the year. The weighted-average diluted shares outstanding during the year was 45.9 million shares.

Cash Generation and Capital Deployment

Total cash flows provided by operating activities for the fourth quarter were $62 million, which represented a decrease from the comparable prior year quarter. This decrease was primarily due to one more payroll payment in the current quarter and a net increase in working capital investments in Marine Corps platform integration and IT services programs ($7 million). These decreases were partially offset by cost savings initiatives in the current quarter ($6 million) and lower interest payments ($4 million). —

Total cash flows provided by operating activities for the year were $273 million, an increase from the prior year, primarily due to a net reduction in working capital investments in Marine Corps platform integration and IT services programs ($34 million), strong customer receipts, and lower payments for acquisition and integration costs ($13 million) and income taxes ($7 million). Cash flows also were higher due to one additional quarter of operating activities of Scitor. These increases were partially offset by higher interest payments due to one additional quarter of interest incurred on additional borrowings ($13 million) and one extra payroll payment in the current year.

During the quarter SAIC deployed $51 million of capital, consisting of $13 million in cash dividends and $38 million in plan share repurchases (457 thousand shares) under SAIC’s previously announced share repurchase program. For the year, cash dividends were $54 million and share repurchases totaled $149 million (approximately 2.4 million shares), with total share repurchases since the inception of the program in 2013 totaling $349 million (approximately 7.1 million shares).

Quarterly Dividend Declared

Subsequent to fiscal year-end, the Company’s Board of Directors declared a cash dividend of $0.31 per share of the Company’s common stock payable on April 28, 2017 to stockholders of record on April 14, 2017. SAIC intends to continue paying dividends on a quarterly basis, although the declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements and other factors.

New Business Awards

Net bookings for the quarter were approximately $0.8 billion, which reflects a book-to-bill ratio of approximately 0.8. Net bookings for the year were approximately $5.3 billion, which reflects a book-to-bill ratio of approximately 1.2, our strongest annual book to bill to date, achieved as a result of our go-to-market strategy against an expanding pipeline of contract opportunities. SAIC’s estimated backlog of signed business orders at the end of fiscal 2017 was approximately $8.0 billion of which $1.8 billion was funded.

SAIC was awarded the following notable contracts during the quarter:

U.S. Army – Human Resources Command (HRC): SAIC was awarded a bridge contract to continue to provide the U.S. Army HRC with full life-cycle information technology support, including maintenance, enhancement and development support for systems, programs, applications and databases that are vital to managing the Army’s personnel in peacetime and at war. The bridge contract has a one-year period of performance and a total contract value of $73 million.

U.S. Navy – Space and Naval Warfare Systems Center (SSC) Pacific: SAIC was awarded an indefinite delivery, indefinite quantity (IDIQ) contract by the SSC Pacific to continue to provide network service solutions and engineering support to U.S. Navy and joint Department of Defense shore units worldwide. The multiple-award contract has a three-year base period of performance with two one-year option ordering periods and a total potential value of $84 Million. SAIC is one of four awardees.

Defense Logistics Agency (DLA): SAIC was awarded a new IDIQ contract by the DLA to provide a variety of information technology support services. The multiple-award contract has a five-year base period of performance and one three-year option for a potential contract award ceiling of $6 billion. SAIC is one of 142 awardees.

SAIC was awarded the following notable contracts subsequent to the end of the quarter:

U.S. Army Contracting Command-Redstone: SAIC was awarded a new position on an IDIQ contract in support of the Army Space and Missile Defense Command/Army Forces Strategic Command’s Design, Development, Demonstration and Integration, or D3I, Domain 1 – space, high altitude and missile defense program. The multiple-award contract has a five-year base period of performance and two consecutive two-year options for a total value of more than $3 billion for all awardees. SAIC is one of eight awardees.

Webcast Information

SAIC management will discuss operations and financial results in an earnings conference call beginning at 8 a.m. Eastern time on March 30, 2017. The conference call will be webcast simultaneously to the public through a link on the Investor Relations section of the SAIC website (http://investors.saic.com). We will be providing webcast access only – “dial-in” access is no longer available. Additionally, a supplemental presentation will be available to the public through links to the Investor Relations section of the SAIC website. After the call concludes, an on-demand audio replay of the webcast can be accessed on the Investor Relations website.

(1)

 

Non-GAAP measure, see Schedule 5 for information about this measure.

 

About SAIC

SAIC is a premier technology integrator providing full life cycle services and solutions in the technical, engineering, intelligence, and enterprise information technology markets. SAIC is Redefining Ingenuity through its deep customer and domain knowledge to enable the delivery of systems engineering and integration offerings for large, complex projects. SAIC’s approximately 15,500 employees are driven by integrity and mission focus to serve customers in the U.S. federal government. Headquartered in McLean, Virginia, SAIC has annual revenues of approximately $4.5 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.

Forward-Looking Statements

Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Actual performance and results may differ materially from the guidance and other forward-looking statements made in this release depending on a variety of factors, including: developments in the U.S. government defense budget, including budget reductions, implementation of spending cuts (sequestration) or changes in budgetary priorities; delays in the U.S. government budget process or approval to raise the U.S. debt ceiling; delays in the U.S. government contract procurement process or the award of contracts; delays or loss of contracts as a result of competitor protests; changes in U.S. government procurement rules, regulations and practices; our compliance with various U.S. government and other government procurement rules and regulations; governmental reviews, audits and investigations of our company; our ability to effectively compete and win contracts with the U.S. government and other customers; our ability to retain key employees and customers of recently acquired Scitor Holdings, Inc. and its subsidiaries (collectively, Scitor); our ability to successfully integrate Scitor, including implementing IT and other control systems relating to Scitor’s operations; our ability to generate sufficient earnings to meet the required leverage ratio under our credit facilities, which if unsuccessful would give lenders the right to, among other things, foreclose on all of our assets; our ability to attract, train and retain skilled employees, including our management team, and to obtain security clearances for our employees; our ability to accurately estimate costs associated with our firm-fixed price and other contracts; cybersecurity, data security or other security threats, systems failures or other disruptions of our business; resolution of legal and other disputes with our customers and others or legal or regulatory compliance issues; our ability to effectively deploy capital and make investments in our business; our ability to maintain relationships with prime contractors, subcontractors and joint venture partners; our ability to manage performance and other risks related to customer contracts, including complex engineering projects; the adequacy of our insurance programs designed to protect us from significant product or other liability claims; our ability to declare future dividends based on our earnings, financial condition, capital requirements and other factors, including compliance with applicable laws and contractual agreements; and our ability to execute our business plan and long-term management initiatives effectively and to overcome these and other known and unknown risks that we face. These are only some of the factors that may affect the forward-looking statements contained in this release. For further information concerning risks and uncertainties associated with our business, please refer to the filings we make from time to time with the U.S. Securities and Exchange Commission, including the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, which may be viewed or obtained through the Investor Relations section of our website at www.saic.com.

All information in this release is as of March 30, 2017. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.

 
Schedule 1:
 
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED AND CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
 
Three Months Ended Year Ended
   

February 3,
2017

 

January 29,
2016

 

February 3,
2017

 

January 29,
2016

 

(in millions, except per share amounts)

Revenues $ 1,026   $ 1,071 $ 4,450   $ 4,315
Cost of revenues 919 965 4,003 3,904
Selling, general and administrative expenses 46 42 166 158
Acquisition and integration costs         10     10     26
Operating income     61     54     271     227
Interest expense 11 13 52 44
Other income (expense), net     1         1    
Income before income taxes 51 41 220 183
Provision for income taxes     (15 )     (13 )     (72 )     (66 )
Net income   $ 36   $ 28   $ 148   $ 117
Weighted-average number of shares outstanding:
Basic     43.9     45.4     44.5     45.8
Diluted     45.3     47.0     45.9     47.4
Earnings per share:
Basic   $ 0.82   $ 0.61   $ 3.33   $ 2.55
Diluted   $ 0.79   $ 0.60   $ 3.22   $ 2.47
Cash dividends declared and paid per share   $ 0.31   $ 0.31   $ 1.24   $ 1.21
 
 
Schedule 2:
 
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED AND CONSOLIDATED BALANCE SHEETS
(Unaudited)
     
   

February 3,
2017

   

January 29,
2016

(in millions)
ASSETS
Current assets:
Cash and cash equivalents $ 210 $ 195
Receivables, net 539 635
Inventory, prepaid expenses and other current assets     152       122
Total current assets 901 952
Goodwill 863 860
Intangible assets, net 200 224
Property, plant and equipment, net 60 71
Other assets     18       15
Total assets   $ 2,042     $ 2,122
 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued liabilities $ 432 $ 447
Accrued payroll and employee benefits 158 184
Long-term debt, current portion     25       57
Total current liabilities 615 688
Long-term debt, net of current portion 1,022 1,013
Other long-term liabilities 51 41
Total equity     354       380
Total liabilities and equity   $ 2,042     $ 2,122
 
 
Schedule 3:
 
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED AND CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
   
Three Months Ended Year Ended
   

February 3,
2017

 

January 29,
2016

 

February 3,
2017

 

January 29,
2016

(in millions)
Cash flows from operating activities:    
Net income $ 36 $ 28 $ 148 $ 117
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 12 20 53 62
Deferred income taxes 1 3 1 3
Stock-based compensation expense 6 8 31 33
Excess tax benefits from stock-based compensation (3 ) (1 ) (18 ) (10 )
Loss on disposal of property, plant, and equipment 1 1 1 1
Loss on extinguishment of debt 2
Increase (decrease) resulting from changes in operating assets and liabilities net of the effect of the acquisition:
Receivables 77 39 96 (5 )
Inventory, prepaid expenses and other current assets (23 ) (6 ) (36 ) (11 )
Other assets 1 (1 )
Accounts payable and accrued liabilities 12 8 16 44
Accrued payroll and employee benefits (59 ) 11 (26 ) (4 )
Other long-term liabilities     1       (2 )     5       (4 )
Total cash flows provided by operating activities 62 108 273 226
Cash flows from investing activities:
Change in restricted cash 2 2 6 (14 )
Expenditures for property, plant, and equipment (4 ) (9 ) (15 ) (20 )
Asset acquisition (2 )
Cash paid for acquisition, net of cash acquired                       (764 )
Total cash flows used in investing activities (2 ) (7 ) (11 ) (798 )
Cash flows from financing activities:
Dividend payments to stockholders (13 ) (14 ) (54 ) (55 )
Principal payments on borrowings (43 ) (236 ) (72 )
Issuances of stock 2 1 5 4
Stock repurchased and retired or withheld for taxes on equity awards (43 ) (33 ) (180 ) (69 )
Excess tax benefits from stock-based compensation 3 1 18 10
Disbursements for obligations assumed from Scitor acquisition (2 ) (2 ) (7 ) (5 )
Proceeds from borrowings 209 670
Deferred financing costs                 (2 )     (17 )
Total cash flows (used in) provided by financing activities     (53 )     (90 )     (247 )     466  
Total increase (decrease) in cash and cash equivalents 7 11 15 (106 )
Cash and cash equivalents at beginning of period     203       184       195       301  
Cash and cash equivalents at end of period   $ 210     $ 195     $ 210     $ 195  
 
 
Schedule 4:
 
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
BACKLOG
(Unaudited)
 

The estimated value of our total backlog as of the dates presented was:

     
   

February 3,
2017

 

November 4,
2016

 

January 29,
2016

(in millions)
Funded backlog $ 1,811 $ 2,044 $ 1,879
Negotiated unfunded backlog     6,209       6,189       5,319
Total backlog   $ 8,020     $ 8,233     $ 7,198
 

Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts and task orders as work is performed and excludes contract awards which have been protested by competitors until the protest is resolved in our favor. SAIC segregates backlog into two categories, funded backlog and negotiated unfunded backlog. Funded backlog for contracts with government agencies primarily represents contracts for which funding is appropriated less revenues previously recognized on these contracts, and does not include the unfunded portion of contracts where funding is incrementally appropriated or authorized by the U.S. government and other customers even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government agencies represents the estimated value of contracts which may cover multiple future years under which SAIC is obligated to perform, less revenues previously recognized on these contracts. Negotiated unfunded backlog represents the estimated future revenues to be earned from negotiated contracts for which funding has not been appropriated or authorized, and unexercised priced contract options. Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be awarded under indefinite delivery, indefinite quantity (IDIQ), U.S. General Services Administration (GSA) schedules or other master agreement contract vehicles.

 

Schedule 5:

 

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

NON-GAAP FINANCIAL MEASURES

(Unaudited)

 
This schedule describes the non-GAAP financial measures included in this earnings release. While we believe that these non-GAAP financial measures may be useful in evaluating our financial information, they should be considered as supplemental in nature and not as a substitute for financial information prepared in accordance with GAAP. Reconciliations, definitions, and how we believe these measures are useful to management and investors are provided below. Other companies may define similar measures differently.
       

Internal revenue growth

 

Three
Months
Ended

Year
Ended

       

February 3,
2017

(in millions)
Prior year period’s revenues, as reported $ 1,071 $ 4,315
Prior year period’s revenues performed by former Parent (3 ) (31 )
Revenues of acquired business for the pre-acquisition prior year period               154  
Prior year period’s revenues, as adjusted 1,068 4,438
Current year revenues, as reported 1,026 4,450
Revenues performed by former Parent (1 ) (9 )
Estimated impact of 53rd week               (88 )
Current year period’s revenues, as adjusted         1,025       4,353  
Internal revenue growth (contraction)(1)       $ (43 )   $ (85 )
Internal revenue growth (contraction) percentage (4.0 %) (1.9 %)
 

We utilize internal revenue growth (or internal revenue contraction if negative) to evaluate revenue growth after the completion of acquisitions. Internal revenue growth is calculated by comparing our reported revenues for the current year to the reported revenues for the prior year comparable period adjusted to include any pre-acquisition historical revenues of acquired businesses. We also adjust current and prior year revenue to exclude the impact of revenue performed by our former parent company, Leidos Holdings, Inc. (“former Parent”) since revenues on pre-separation joint work are recorded equal to cost and are expected to decline over time. For fiscal 2017, a 53-week fiscal year, we have also adjusted revenue to exclude the estimated impact of the additional week in order to facilitate comparison to the prior year period. We estimate the revenue impact of the additional week by dividing the current year’s revenues for the first quarter by the number of days in the first quarter and multiplying that amount by the number of additional days in the first quarter. We believe that adjusting current year revenues to reflect the impact of the additional week improves comparability since differences in the number of days generally have a direct impact on the amount of revenues earned during the respective periods. We believe that internal revenue growth provides management and investors with useful information in assessing trends on how successful the Company has been in growing revenues as we develop our base business and access new markets and capabilities provided by acquisitions.

(1)

 

Non-GAAP measure, see above for definition.

 
 
Schedule 5 (continued):
 
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES (continued)
(Unaudited)
 
 

Adjusted operating income, EBITDA, Adjusted EBITDA, and Adjusted diluted earnings per share

 

   
Three Months Ended Year Ended
   

February 3,
2017

 

January 29,
2016

 

February 3,
2017

 

January 29,
2016

(in millions, except per share amounts)
                                 
Net income $ 36   $ 28 $ 148   $ 117
Interest expense 11 13 52 44
Provision for income taxes 15 13 72 66
Depreciation and amortization     11       19       50       59  
EBITDA(1) 73 73 322 286
EBITDA as a percentage of revenues 7.1 % 6.8 % 7.2 % 6.6 %
Acquisition and integration costs 10 10 26
Depreciation included in acquisition and integration costs           (3 )     (2 )     (3 )
Adjusted EBITDA(1) $ 73 $ 80 $ 330 $ 309
Adjusted EBITDA as a percentage of revenues     7.1 %     7.5 %     7.4 %     7.2 %
                                 
Operating income $ 61 $ 54 $ 271 $ 227
Operating income as a percentage of revenues 5.9 % 5.0 % 6.1 % 5.3 %
Acquisition and integration costs           10       10       26  
Adjusted operating income(1) $ 61 $ 64 $ 281 $ 253
Adjusted operating income as a percentage of revenues     5.9 %     6.0 %     6.3 %     5.9 %
       
Diluted earnings per share $ 0.79 $ 0.60 $ 3.22 $ 2.47
Acquisition and integration costs, divided by diluted weighted-average number of shares outstanding $ $ 0.21 $ 0.22 $ 0.55
Acquisition and integration costs tax benefit, divided by diluted weighted-average number of shares outstanding   $     $ (0.07 )     (0.09 )     (0.17 )
Adjusted diluted earnings per share(1)   $ 0.79     $ 0.74     $ 3.35     $ 2.85  
 

EBITDA is a performance measure that is calculated by taking net income and excluding interest expense, provision for income taxes, and depreciation and amortization. Adjusted EBITDA, adjusted operating income, and adjusted diluted earnings per share are performance measures that exclude acquisition and integration costs that we do not consider to be indicative of our ongoing operating performance as they relate to the Company’s significant acquisition of Scitor. Adjusted EBITDA and adjusted operating income are calculated by excluding acquisition and integration costs from EBITDA and operating income, respectfully. Adjusted diluted earnings per share is calculated by excluding the impact of acquisition and integration costs from diluted earnings per share. In order to calculate the impact on diluted earnings per share, we use the effective income tax rates for each period excluding the negative effect of certain non-deductible acquisition and integration costs included in net income. We believe that these performance measures provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.

(1)

 

Non-GAAP measure, see above for definition.

 
 
Schedule 5 (continued):
 
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES (continued)
(Unaudited)
 
 

Free Cash Flow

   
Three Months Ended Year Ended
   

February 3,
2017

 

January 29,
2016

 

February 3,
2017

 

January 29,
2016

    (in millions)
Cash flows provided by operating activities $ 62   $ 108 $ 273   $ 226
Expenditures for property, plant, and equipment     (4 )     (9 )     (15 )     (20 )
Free cash flow(1)   $ 58     $ 99     $ 258     $ 206  
 

Free cash flow is calculated by taking cash flows provided by operating activities less expenditures for property, plant, and equipment. We believe that free cash flow provides management and investors with useful information in assessing trends in our cash flows and in comparing them to other peer companies, many of whom present a similar non-GAAP liquidity measure. This measure should not be considered as a measure of residual cash flow available for discretionary purposes.

(1)

 

Non-GAAP measure, see above for definition.

 

Security Thought Leaders at AMAG, Cyberinc and Quantum This Week On SecuritySolutionsWatch.com

/EINPresswire.com/ — NEW YORK, NY–(Marketwired – Mar 30, 2017) – G4S (LSE: GFS).

*****
MARK YOUR CALENDAR!

BORDER SECURITY EXPO
If your mission is border security, this is the most important event of the year!
San Antonio, TX USA
11 – 13 April 2017Henry B. Gonzalez Convention Center, USA

THE INTERNATIONAL SUMMIT ON BORDERS
is the newest addition to the Clarion portfolio, and will be an annual gathering of global leaders focused on the intersection of international trade and travel with homeland security and other transnational threats.
The Army & Navy Club, Washington
13 – 14 June, 2017

2017 ISC WEST
April 5-7, 2017
Sands Expo Las Vegas, NV

THIS PRESS RELEASE IS SUBJECT TO OUR TERMS OF USE, CONDITIONS, AND DISCLAIMER HERE: www.securitysolutionswatch.com/Main/Terms_of_Use.html.

The Mikey Czech Foundation contribuye con 1 millón de dólares a la investigación DIPG del Dana-Farber Cancer Institute

NEW CANAAN, Connecticut, 30 de marzo de 2017 /PRNewswire/ — The Mikey Czech Foundation, Inc. (la „fundación”, www.mikeyczech.org), una fundación sin ánimo de lucro 501(c)(3) creada por medio de Stephen J. y Jennifer L. Czech para financiar la investigación médica de tumores cerebrales pediátricos, anunció la concesión de 1.000.000 dólares para Pediatric Medical Neuro-Oncology de Dana-Farber, dirigido por Mark W. Kieran, doctor, PhD y con sede en Boston, Massachusetts. Esta donación es el mayor regalo único jamás otorgado dedicado a la investigación del glioma pontino intrínseco difuso realizado en la historia de Dana-Farber. Los beneficios de la concesión se han diseñado para mejorar la investigación y desarrollo de los remedios de los tumores cerebrales pediátricos glioma pontino intrínseco difuso („DIPG”), el tipo de tumor que se llevó la vida de James Michael „Mikey” Czech en 2008 a los 11 años.

Los tumores de tronco cerebrales DIPG afectan a los nervios craneales de los niños de entre 3 y 16 años, destruyendo los nervios que suministran los músculos del ojo y rostro, además de los músculos implicados en la deglución. Los síntomas incluyen doble visión, incapacidad de cerrar por completo los párpados, „caída” de un lado del rostro y dificultad para mascar y deglutir. El tumor afecta además a las „pistas largas” del cerebro, con la debilidad resultante en los brazos o piernas y la complicación de hablar y caminar. Al tiempo que crece el tumor, el niño pierde principalmente su capacidad de usar las extremidades. Después, pierde de forma secuencial su capacidad para deglutir y respirar. Pese a su deterioro físico, el niño mantiene sus facultades mentales y es completamente consciente de lo que le está sucediendo. La supervivencia tras 12 o 14 meses no es normal, y las nuevas aproximaciones de cara al tratamiento de estos tumores son muy necesarias ya que no existen terapias eficaces actualmente para el tratamiento de los DIPGs.

„Los activos adquiridos para curar los DIPGs consisten en: (a) una fuente de fondos sostenibles; (b) neuro-oncólogos de nivel mundial; e (c) instalaciones de investigación de última generación”, afirmó Steve Czech, padre de Mikey y presidente y cofundador de The Mikey Czech Foundation. „Queremos ser una fuente de fondo sostenible, y creemos que el doctor Kieran, sus colegas y Dana-Farber representan ‚lo mejor de su clase’ en relación a la investigación de neuro-oncología pediátrica y las instalaciones de investigación de última generación. Esta donación es nuestro segunda de las que esperamos sean una serie de donaciones, comparables o de mayor tamaño, diseñados para erradicar esta enfermedad cruel”.

Además de sus esfuerzos con la fundación, Steve Czech es el socio administrativo y responsable de operaciones de Czech Asset Management, L.P., un gestor de inversiones alternativas centrado en los créditos con sede en Greenwich, CT, que dispone de unos 4.300 millones de dólares en capital comprometido bajo gestión y una capacidad de inversión conjunta estacada. En un esfuerzo por establecer una fuente de fondo sostenible para la investigación del DIPG, Czech contribuye con un porcentaje de sus ingresos personales a la investigación del DIPG.

„Los fondos de The Mikey Czech Foundation son vitales, ya que nos permitirán seguir realizando investigaciones para definir los cambios moleculares subyacentes en DIPG que anteriormente habían hecho a estos tumores muy resistentes a la terapia”, destacó Mark W. Kieran, doctor, PhD y director de neuro-oncología pediátrica médica del Dana-Farber Cancer Institute. „Estos esfuerzos llevados a cabo ya han presentado un impacto notable. El primer ensayo clínico nacional de biopsia del DIPG y de la clasificación molecular seguido de un tratamiento individualizado de la aberración específica en el tumor de cada uno de los pacientes (el primero ensayo de esta clase en el mundo) ya se ha completado. De estos esfuerzos llega el descubrimiento de cómo se produce el DIPG en forma de tres variantes diferentes con firmas moleculares únicas que presentan mutaciones diferentes, algunas de ellas únicas de DIPG y desconocidas en cualquier otro tipo de cáncer. Dana-Farber ya está desarrollando terapias destinadas contra estas mutaciones con la esperanza de que finalmente podamos comenzar a llevar a cabo un impacto considerable en el tratamiento de esta enfermedad. Todos estos esfuerzos se han producido gracias a la dedicación de los pacientes, sus familias y fundaciones, incluyendo The Mikey Czech Foundation, y no hubieran sido posibles sin ellos”.

„El DIPG es una enfermedad devastadora para pacientes pediátricos y sus familiares. Con el fondo de la Mikey Czech Foundation, el doctor Kieran puede continuar con esta investigación destacada y esperamos que un día encuentre la cura para el DIPG”, expresó Laurie H. Glimcher, doctora y directora general y consejera delegada del Dana-Farber Cancer Institute.

Acerca de The Mikey Czech Foundation: The Mikey Czech Foundation, Inc. (la „fundación”) es una fundación sin ánimo de lucro 501(c)(3) establecida por la familia de Mikey para llevar a cabo la financiación de la investigación médica para tumores cerebrales pediátricos, incluyendo los tumores de tronco cerebrales pediátricos del glioma pontino intrínseco difuso („DIPG”). Los tumores de tronco cerebrales DIPG son muy poco habituales. A nivel nacional se informa de unos 300 casos al año, lo que desgraciadamente los lleva a quedar relegados como una forma de cáncer con categoría „huérfana” dentro de la comunidad de investigación médica, ya que son muy pocos los niños que desarrollan este tipo de tumores cerebrales que garantizan una inversión necesaria que cuenta con escasos dólares en medicina para encontrar una cura. La fundación aprobará becas que apoyan la investigación en las instalaciones de cuidado de salud, formación e investigación médica en Estados Unidos para ayudar a la investigación en esta área.

Acerca del Diffuse Intrinsic Pontine Glioma („DIPG”): Los tumores de tronco cerebrales afectan a los nervios del cráneo, causando síntomas relacionados con los nervios que suministran los músculos del ojo y rostro, además de los músculos implicados en la deglución. Estos síntomas incluyen la doble visión, incapacidad de cerrar por completo los párpados, „caída” de un lado del rostro y dificultad para mascar y deglutir. El tumor afecta además a las „pistas largas” del cerebro, con la debilidad resultante en los brazos o piernas y la complicación de hablar y caminar. Al tiempo que crece el tumor, el niño pierde principalmente su capacidad de usar las extremidades. Después, pierde de forma secuencial su capacidad para deglutir y respirar, y empieza a padecer alteraciones del ritmo cardiaco. Pese a su deterioro físico, el niño mantiene sus facultades mentales y es completamente consciente de lo que le está sucediendo.

Los síntomas suelen empeorar rápidamente porque el tumor crece con rapidez. Los síntomas de los pacientes a menudo mejoran de forma considerable durante o tras seis semanas de radiación. Por desgracia, los problemas normalmente suelen ser recurrentes tras una media de seis meses, y progresan con velocidad. La supervivencia tras 12 o 14 meses no es normal, y casi todos los niños fallecen a causa de la enfermedad en un periodo de entre 2 y 3 años. Las nuevas aproximaciones de cara al tratamiento de estos tumores son muy necesarias de forma urgente.

Acerca del Dana-Farber Cancer Institute: Desde la consecución de las primeras remisiones del cáncer con quimioterapia en el año 1948 hasta el desarrollo de las nuevas terapias más novedosas, el Dana-Farber Cancer Institute es uno de los principales centros de cáncer del mundo en investigación y tratamiento sobre el cáncer. Se trata del único centro clasificado en el top 4 del U.S. News and World Report’s Best Hospitals para cuidado del cáncer a nivel pediátrico y de adulto.

Dana-Farber está en el centro de un amplio abanico de esfuerzos de colaboración para reducir la carga del cáncer a través de las consultas científicas, cuidado clínico, formación, dedicación de la comunidad y abogacía. Dana-Farber/Brigham y el Women’s Cancer Center proporcionan lo último en cuidado del cáncer para adultos; Dana-Farber/Boston Children’s Cancer y el Blood Disorders Center para niños. El Dana-Farber/Harvard Cancer Center une los esfuerzos de investigación del cáncer de cinco centros médicos académicos de Harvard y dos escuelas de graduados, mientras que el Dana-Farber Community Cancer Care proporciona tratamiento de calidad contra el cáncer en comunidades de fuera del Longwood Medical Area de Boston.  

Dana-Farber se dedica a conseguir un equilibrio único 50/50 entre la investigación del cáncer y su cuidado, al igual que buena parte del trabajo del instituto se dedica a traducir los resultados del descubrimiento en nuevos tratamientos para pacientes de forma local, y en todo el mundo.

Acerca de Stephen J. Czech: Steve Czech cuenta con más de 28 años de experiencia en créditos y finanzas corporativas, y tiene sólidos antecedentes en la creación y administración de fondos de crédito de préstamos directos. Su experiencia incluye provisión, estructuración, evaluación de riesgo, monitorización y reestructuración de préstamos corporativos. Antes de crear Czech Asset Management, Steve estuvo empleado en varias destacadas empresas, incluyendo pero no limitándose, Morgan Stanley, Credit Suisse Group AG, Donaldson, Lufkin & Jenrette („DLJ”) y Banc of America Securities LLC. Czech and his family are significant donors to, and advocates of, causes related to: (i) terminally-ill children, (ii) active-duty and retired Navy SEALs and their families; (iii) first-responders (ie: Police, Fire and EMTs); and (iv) scholarships for underprivileged high-school students throughout the United States. Czech es el fundador y co-presidente de The Mikey Czech Foundation, miembro de The Navy SEAL Foundation National Leadership Council, miembro de la Advisory Board of The University of Chicago Booth School of Business, miembro laureado de la Dean’s Society of The University of Chicago Booth School of Business, miembro del Villanova University’s President’s Club & Parents Executive Committee, miembro de la Aesclepian Society of Dana-Farber Cancer Institute y miembro del Dana-Farber Presidential Visiting Committee for Pediatric Oncology. Czech es además el presidente del consejo de administración de Alfred Angelo, Inc. Czech tiene un B.S. otorgado por Marquette University y un MBA otorgado por la Booth School of Business de University of Chicago.

Acerca de Czech Asset Management, L.P. Czech Asset Management, L.P., que cuenta con unos 4.300 millones de dólares de capita comprometido bajo gestión y una capacidad de inversión conjunta destacada, es una firma de préstamo directo con sede en Greenwich, CT, dedicada al suministro de activos basados en la negociación privada y flujo de caja primario y préstamos asegurados senior de tipo flotantes principalmente en compañías de mercado medio de Estados Unidos que generan unos ingresos anuales de entre 75 millones de dólares y 500 millones de dólares o más, además de una cifra EBITDA anual de entre 7,5 millones de dólares hasta 50 millones de dólares.

SOURCE The Mikey Czech Foundation, Inc.

The Mikey Czech Foundation doa $ 1 milhão para a pesquisa do GPID no Instituto do Câncer Dana-Farber

NEW CANAAN, Connecticut, 30 de março de 2017 /PRNewswire/ — The Mikey Czech Foundation, Inc. (a „Fundação”, www.mikeyczech.org), uma fundação sem fins lucrativos 501(c)(3) estabelecida por Stephen J. e Jennifer L. Czech para financiar pesquisas médicas de tumores cerebrais pediátricos, anunciou a doação de $ 1.000.000 ao departamento de Neuro-Oncologia Médica Pediátrica do Instituto Dana-Farber, chefiado por Mark W. Kieran, MD, PhD, e localizado em Boston, Massachusetts. A doação é a maior contribuição já realizada por um único doador para a pesquisa do glioma pontino intrínseco difuso („GPID”) na história do Dana-Farber. O dinheiro da doação será empregado na pesquisa e desenvolvimento de remédios para tumores cerebrais pediátricos do glioma pontino intrínseco difuso, o tipo de tumor que tirou a vida de James Michael „Mikey” Czech em 2008, aos 11 anos de idade.

Os tumores do tronco cerebral GPID afetam os nervos cranianos de crianças, de 3 a 16 anos de idade, destruindo os nervos que suprem os músculos dos olhos e da face, bem como os músculos envolvidos na deglutição. Os sintomas incluem visão dupla, incapacidade de fechar as pálpebras completamente, „languidez” em um lado da face e dificuldade para mastigar e deglutir. O tumor também afeta as „vias longas” do cérebro, resultando em fraqueza nos braços e nas pernas e dificuldades para falar e andar. Conforme o tumor cresce, as crianças perdem, inicialmente, a capacidade de usar seus membros. Depois disso, elas perdem, em sequência, sua capacidade de deglutir e respirar. Apesar de sua deterioração física, as crianças mantêm suas faculdades mentais e têm plena consciência do que está acontecendo com elas. A sobrevivência além de 12 a 14 meses é incomum. Novos métodos de tratamento desses tumores são necessários, urgentemente, porque não existem terapias eficazes, conhecidas atualmente, para o tratamento de GPIDs.

„Os recursos necessários para curar GPIDs consistem de: (a) uma fonte de financiamento sustentável; (b) neuro-oncologistas de nível internacional; e (c) instalações de pesquisa avançadas”, disse o pai de Mikey Steve Czech, presidente e cofundador da The Mikey Czech Foundation, Steve Czech. „Pretendemos ser a fonte de financiamento sustentável e acreditamos que o Dr. Kieran, seus colegas e o Dana-Farber são os melhores de sua classe no que diz respeito à pesquisa da neuro-oncologia pediátrica e têm instalações de pesquisa avançadas. Essa doação é a segunda que fazemos e esperamos manter uma série de doações, comparáveis ou maiores, dedicadas a erradicar essa doença abominável”.

Além de seus esforços na Fundação, Steve Czech é o sócio administrativo e CIO (chief investment officer) da Czech Asset Management, L.P., uma gestora de investimentos alternativos focados em crédito sediada em Greenwich, Connecticut, com aproximadamente $ 4,3 bilhões de capital comprometido sob sua administração e capacidade de coinvestimento significativa. Em um esforço para estabelecer uma fonte de financiamento sustentável para a pesquisa do GPID, o sr. Czech contribui com uma percentagem de sua renda pessoal para a pesquisa do GPID.

„O financiamento da The Mikey Czech Foundation é fundamental porque ele nos permite dar continuidade à pesquisa para definir as mudanças moleculares básicas no GPID, que tornaram, anteriormente, esses tumores tão resistentes à terapia”, disse o diretor de Neuro-Oncologia Médica Pediátrica do Instituto de Câncer Dana-Farber, Mark W. Kieran. „Esses esforços já estão exercendo um impacto. O primeiro estudo clínico nacional de biópsia do GPID e a classificação molecular seguida por tratamento individualizado para a anomalia específica em cada tumor do paciente (o primeiro estudo clínico do tipo no mundo) já foi concluído. Desses esforços, veio a descoberta de que o GPID ocorre como três variantes diferentes com características moleculares únicas que têm mutações diferentes, algumas das quais eram únicas do GPID e desconhecidas em quaisquer outros tipos de câncer. O instituto Dana-Farber está desenvolvendo agora terapias dirigidas a essas mutações, na esperança de que possamos finalmente começar a exercer um impacto significativo no tratamento dessa doença. Todo esse esforço veio da dedicação de pacientes, suas famílias e fundações, incluindo a The Mikey Czech Foundation, e isso não teria sido possível sem eles”.

„O GPID é uma doença devastadora para pacientes pediátricos e suas famílias. Com o financiamento da The Mikey Czech Foundation, o Dr. Kieran pode dar continuidade a sua importante pesquisa e, esperançosamente, encontrar um dia a cura para o GPID”, disse a presidente e CEO do Instituto do Câncer Dana-Farber, Laurie H. Glimcher, MD.

Sobre a The Mikey Czech Foundation: A The Mikey Czech Foundation, Inc. (a „Fundação”) é uma fundação sem fins lucrativos 501(c)(3) estabelecida pela família de Mikey para financiar a pesquisa médica de tumores cerebrais pediátricos, incluindo os tumores do tronco cerebral pediátrico do glioma pontino intrínseco difuso („GPID”). Os tumores do tronco cerebral pediátrico do GPID são extremamente raros. Aproximadamente 300 casos por ano são relatados em todo o país, o que, infelizmente, relega esse tipo de câncer para um status „órfão” dentro da comunidade de pesquisa médica, porque muito poucas crianças desenvolvem esse tipo de tumor cerebral para justificar o investimento necessário dos escassos recursos financeiros para a pesquisa médica destinada a encontrar a cura. A Fundação irá conceder verbas para dar suporte à pesquisa em instalações de tratamento de saúde, educação e pesquisa médica em todos os Estados Unidos, para prestar assistência à pesquisa nessa área.

Sobre o glioma pontino intrínseco difuso („GPID”): Tumores do tronco cerebral afetam os nervos cranianos, causando sintomas relacionados aos nervos que suprem os músculos dos olhos e da face, bem como os músculos envolvidos na deglutição. Esses sintomas incluem visão dupla, incapacidade de fechar as pálpebras completamente, „languidez” em um lado da face e dificuldade para mastigar e deglutir. O tumor também afeta as „vias longas” do cérebro, resultando em fraqueza nos braços e nas pernas e dificuldades para falar e andar. Conforme o tumor cresce, as crianças perdem, inicialmente, a capacidade de usar seus membros. Depois disso, elas perdem, em sequência, o controle de sua capacidade de deglutir e respirar e começam a sofrer alterações em seus batimentos cardíacos. Apesar da deterioração física, as crianças mantêm suas faculdades mentais e têm plena consciência do que está acontecendo com elas.

Normalmente, os sintomas pioram rapidamente por causa do rápido crescimento do tumor. Com frequência, os sintomas do paciente melhoram substancialmente durante ou após seis semanas de radiação. Infelizmente, os problemas são normalmente recorrentes, voltando após seis meses, em média, e progredindo rapidamente. A sobrevivência após um período de 12 a 14 meses é incomum e quase todas as crianças não resistem à doença após 2 ou 3 anos. Novos métodos para tratar esses tumores são necessários urgentemente.

Sobre o Instituto do Câncer Dana-Farber: De conseguir as primeiras remissões no câncer com quimioterapia, em 1948, a desenvolver as últimas terapias, o Instituto do Câncer Dana-Farber é um dos principais centros de pesquisa e tratamento do câncer no mundo. É o único centro classificado entre os 4 Melhores Hospitais dos EUA pela News and World Report para o tratamento do câncer em adultos e crianças.

O instituto Dana-Farber está no centro de uma grande variedade de esforços colaborativos para reduzir o ônus do câncer, através de investigação científica, tratamento clínico, educação, envolvimento comunitário e o combate à doença. O Dana-Farber/Brigham and Women’s Cancer Center fornece os últimos tratamentos do câncer para adultos; o Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, para crianças. O Dana-Farber/Harvard Cancer Center une os esforços da pesquisa do câncer de cinco centros médicos acadêmicos de Harvard e duas escolas de pós-graduação, enquanto o Dana-Farber Community Cancer Care fornece tratamento de alta qualidade do câncer em comunidades fora da Longwood Medical Area (Área Médica de Longwood) de Boston.

O instituto Dana-Farber se dedica a encontrar um equilíbrio 50/50 entre a pesquisa e o tratamento do câncer e muito do trabalho do instituto é dedicado a traduzir os resultados de suas descobertas em novos tratamentos de pacientes, localmente e em todo o mundo.

Sobre Stephen J. Czech: Steve Czech tem mais de 28 anos de experiência nas áreas de crédito e finanças corporativas, bem como um longo histórico em estabelecer e operar fundos de concessão de créditos de empréstimos diretos. Sua experiência inclui contratação, estruturação, concessão de crédito (underwriting), monitoramento e reestruturação de empréstimos corporativos. Antes de formar a Czech Asset Management, Steve trabalhou em diversas empresas proeminentes, incluindo, sem se limitar a, Morgan Stanley, Credit Suisse Group AG, Donaldson, Lufkin & Jenrette („DLJ”) e Banc of America Securities LLC. Czech e sua família são doadores expressivos a causas, que defendem, relacionadas a: (i) crianças com doenças terminais; (ii) militares da ativa e aposentados da Navy SEAL e suas famílias: (iii) socorristas (isto é, policiais, bombeiros e técnicos em emergências médicas — EMTs); (iv) bolsas de estudo para estudantes desfavorecidos do ensino secundário nos Estados Unidos. Czech é fundador e copresidente da The Mikey Czech Foundation, membro da The Navy SEAL Foundation National Leadership Council, membro do Advisory Board of The University of Chicago Booth School of Business, membro laureado da Dean’s Society of The University of Chicago Booth School of Business, membro da Villanova University’s President’s Club & Parents Executive Committee, membro da Aesclepian Society of Dana-Farber Cancer Institute e membro do Dana-Farber Presidential Visiting Committee for Pediatric Oncology. Czech também é o presidente do Conselho da Alfred Angelo, Inc. Czech é formado pela Universidade de Marquette e fez mestrado na University of Chicago Booth School of Business.

Sobre a Czech Asset Management, L.P. A Czech Asset Management, L.P., com aproximadamente $ 4,3 bilhões em capital comprometido sob sua administração e capacidade de coinvestimento significativa, é uma firma de empréstimos diretos sediada em Greenwich, Connecticut, dedicada em fornecer empréstimos preferenciais garantidos com taxa flutuante garantida de primeiro e segundo penhor baseados em ativos e fluxo de caixa, negociado privadamente, primariamente para empresas do mercado de nível médio nos EUA, que geram receitas anuais de $ 75,0 milhões a $ 500,0 milhões e EBITDA anual de $ 7,5 milhões a $ 50,0 milhões.

FONTE The Mikey Czech Foundation, Inc.

SOURCE The Mikey Czech Foundation, Inc.

La fondation The Mikey Czech Foundation contribue à hauteur de 1 million $ à la recherche sur le DIPG au Dana-Farber Cancer Institute

NEW CANAAN, Connecticut, le 30 mars 2017 /PRNewswire/ — La fondation The Mikey Czech Foundation, Inc. (la « fondation », www.mikeyczech.org) une fondation à but non lucratif 501(c)(3) fondée par Stephen J. et Jennifer L. Czech afin de financer la recherche médicale pour les tumeurs cérébrales pédiatriques, a annoncé un don de 1 000 000 $ pour le Pediatric Medical Neuro-Oncology du Dana-Farber, dirigé par Mark W. Kieran, MD, PhD, et situé à Boston, Massachusetts. Le don est le plus important jamais effectué par un donateur unique destiné à la recherche sur le gliome pontique intrinsèque diffus dans l’histoire de Dana-Farber. Les produits du don visent à faire avancer la recherche et le développement de remèdes pour les tumeurs cérébrales pédiatriques gliome pontique intrinsèque diffus (« DIPG »), le type de tumeur qui a réclamé la vie de James Michael « Mikey » Czech en 2008 à l’âge de 11 ans.

Les tumeurs du tronc cérébral DIPG affectent les nerfs crâniens d’enfants âgés de 3 à 16 ans, détruisant les nerfs qui alimentent les muscles des yeux et du visage ainsi que les muscles impliqués dans la déglutition. Les symptômes incluent une vision dédoublée, une incapacité à fermer complètement les paupières, « l’affaissement » d’un côté du visage et la difficulté à mâcher et à déglutir. La tumeur affecte également les « voies longues » du cerveau, avec une faiblesse consécutive des bras et des jambes, ainsi qu’une difficulté à parler et à marcher. À mesure que la tumeur se développe, les enfants perdent initialement leur capacité à utiliser leurs membres. Par la suite, ils perdent successivement le contrôle de leur capacité à avaler et à respirer et commencent à avoir des altérations de la fréquence cardiaque. Nonobstant leur détérioration physique, les enfants conservent leurs facultés mentales et sont complètement au fait de ce qui leur arrive. La survie au-delà de 12 à 14 mois est rare et de nouvelles approches pour traiter ces tumeurs s’imposent de toute urgence, car aucune thérapie efficace connue n’existe actuellement pour traiter les DIPG.

« Les actifs requis pour guérir les DIPG consistent en : (a) une source de financement durable ; (b) des neurooncologues d’envergure mondiale ; et (c) des établissements de recherche à la pointe de la technologie », a déclaré Steve Czech, le père de Mikey et le président et cofondateur de la fondation The Mikey Czech Foundation. « Nous entendons être la source de financement durable et nous pensons que le Dr Kieran, ses collègues et Dana-Farber représentent les ”meilleurs dans leur domaine” en matière de recherche en neurooncologie pédiatrique et d’établissements de recherche de pointe. Ce don est le second de ce que nous espérons être une série de dons, de taille comparable ou de plus grande envergure, conçus pour éradiquer cette maladie abominable. »

En plus de ses efforts avec la fondation, Steve Czech est l’associé directeur et directeur des investissements de Czech Asset Management, L.P., un gestionnaire d’investissements alternatifs axés sur les crédits situé à Greenwich, dans le Connecticut, avec approximativement 4,3 milliards $ de capital engagé sous gestion et une capacité de co-investissement significative. Dans le but de créer une source de financement durable pour la recherche sur le DIPG, M. Czech contribue à hauteur d’un pourcentage de ses revenus personnels à la recherche sur le DIPG.

« Le financement de la part de la fondation The Mikey Czech Foundation est essentiel, car il nous permet de continuer à mener des recherches pour définir les modifications moléculaires sous-jacentes dans le DIPG, qui ont précédemment rendu ces tumeurs si résistantes à la thérapie », a déclaré Mark W. Kieran, MD, PhD, directeur du Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute. « Ces efforts ont d’ores et déjà un impact. Le premier essai clinique national de biopsie du DIPG et la classification moléculaire suivie du traitement individualisé de l’aberration spécifique dans chaque tumeur du patient (le premier essai de ce type au monde) est déjà terminé. Ces efforts ont permis de découvrir que le DIPG se produit sous trois variantes différentes avec des signatures moléculaires uniques qui ont différentes mutations, certaines d’entre elles étant uniques au DIPG et inconnues dans d’autres formes de cancers. Dana-Farber développe à présent des thérapies ciblées contre ces mutations dans l’espoir de pouvoir enfin commencer à avoir un impact significatif dans le traitement de cette maladie. Tous ces efforts sont le fruit du dévouement des patients, de leurs familles et de fondations, dont la fondation The Mikey Czech Foundation, et n’auraient pu être possibles sans eux. »

« Le DIPG est une maladie dévastatrice pour les patients pédiatriques et leurs familles. Avec le financement de la fondation The Mikey Czech Foundation, le Dr Kieran peut poursuivre ses importantes recherches et, avec un peu de chance, trouvera un jour un traitement pour le DIPG », a déclaré Laurie H. Glimcher, MD, présidente et PDG du Dana-Farber Cancer Institute.

À propos de la fondation The Mikey Czech Foundation : The Mikey Czech Foundation, Inc. (la « fondation ») est une fondation sans but lucratif 501(c)(3) fondée par la famille de Mikey afin de financer la recherche médicale sur les tumeurs cérébrales pédiatriques, et notamment les tumeurs du tronc cérébral gliome pontique intrinsèque diffus (« DIPG »). Les tumeurs du tronc cérébral DIPG sont extrêmement rares. Environ 300 cas par an sont signalés au niveau national, ce qui malheureusement, relègue cette forme de cancer au statut « d’orphelin » au sein de la communauté de la recherche médicale, car trop peu d’enfants développent ce type de tumeurs cérébrales pour justifier l’investissement de fonds peu abondants pour la recherche médicale nécessaires pour trouver un traitement. La fondation approuvera les subventions pour soutenir la recherche dans les établissements de soins, de formation et de recherche médicale aux États-Unis pour contribuer à la recherche dans ce domaine.

À propos du gliome pontique intrinsèque diffus (« DIPG ») : Les tumeurs du tronc cérébral affectent les nerfs crâniens, provoquant des symptômes liés aux nerfs qui alimentent les muscles des yeux et du visage ainsi que les muscles impliqués dans la déglutition. Ces symptômes incluent une vision dédoublée, une incapacité à fermer complètement les paupières, « l’affaissement » d’un côté du visage et la difficulté à mâcher et à déglutir. La tumeur affecte également les « voies longues » du cerveau, avec une faiblesse consécutive des bras et des jambes, ainsi qu’une difficulté à parler et à marcher. À mesure que la tumeur se développe, les enfants perdent initialement leur capacité à utiliser leurs membres. Par la suite, ils perdent successivement le contrôle de leur capacité à avaler et à respirer et commencent à avoir des altérations de la fréquence cardiaque. Nonobstant leur détérioration physique, les enfants conservent leurs facultés mentales et sont complètement au fait de ce qui leur arrive.

Les symptômes empirent généralement rapidement, car la tumeur croît rapidement. Les symptômes de patients s’améliorent souvent radicalement pendant ou après six semaines de rayonnement. Malheureusement, les problèmes réapparaissent généralement après six mois en moyenne et évoluent rapidement. La survie au-delà de 12 à 14 mois est rare et pratiquement tous les enfants succombent à la maladie en l’espace de 2 à 3 ans. De nouvelles approches pour traiter ces tumeurs s’imposent de toute urgence.

À propos du Dana-Farber Cancer Institute : De la réalisation des premières rémissions du cancer avec la chimiothérapie en 1948 au développement de nouvelles thérapies les plus récentes, le Dana-Farber Cancer Institute est l’un des principaux centres de recherche et de traitement du cancer au monde. Il est le seul centre classé dans les quatre meilleurs hôpitaux américains du News and World Report pour le traitement du cancer chez les adultes et les enfants.

Dana-Farber se trouve au cœur d’un large éventail d’efforts collaboratifs pour réduire la charge du cancer par le biais d’enquêtes scientifiques, de soins cliniques, de formation, d’engagement communautaire et de la promotion de la défense de la cause. Le centre Dana-Farber/Brigham and Women’s Cancer Center procure des soins contre le cancer les plus récents pour les adultes ; le centre Dana-Farber/Boston Children’s Cancer and Blood Disorders Center pour les enfants. Le centre Dana-Farber/Harvard Cancer Center unit les efforts de recherche sur le cancer de cinq centres médicaux universitaires d’Harvard et de deux écoles de cycle supérieur, alors que le centre Dana-Farber Community Cancer Care procure un traitement contre le cancer de grande qualité aux communautés situées en dehors de la zone médicale Longwood de Boston.

Dana-Farber consacre un équilibre 50/50 unique entre la recherche sur le cancer et les soins, et une grande partie du travail de l’institut est dédiée à la traduction des résultats de ces découvertes en nouveaux traitements pour les patients à l’échelle locale et mondiale.

À propos de Stephen J. Czech : Steve Czech compte plus de 28 années d’expérience dans le crédit et le financement de sociétés, ainsi que dans la création et la gestion de fonds de crédits prêteurs directs. Son expérience inclut la recherche de candidats, la structuration, la souscription hypothécaire, le suivi et la restructuration de prêts aux entreprises. Avant de former Czech Asset Management, Steve a été employé par plusieurs sociétés réputées, et notamment, sans toutefois s’y limiter, Morgan Stanley, Crédit Suisse Group AG, Donaldson, Lufkin & Jenrette (« DLJ ») et Banc of America Securities LLC. Czech et sa famille sont des donateurs significatifs et des défenseurs de causes liées aux : (i) enfants en phase terminale, (ii) Navy SEAL en service actif et retraités ainsi qu’à leurs familles, (iii) premiers intervenants (p. ex. : la police, les pompiers et les ambulanciers) , et (iv) à la scolarité pour les élèves du secondaire défavorisés aux États-Unis. Steve est le fondateur et co-président de la fondation The Mikey Czech Foundation, un membre du Navy SEAL Foundation National Leadership Council, un membre du Comité consultatif de l’Université Chicago Booth School of Business, membre lauréat de la Dean’s Society de l’Université Chicago Booth School of Business, un membre du Comité de direction du President’s Club & Parents de l’Université de Villanova, un membre de l’Aesclepian Society of Dana-Farber Cancer Institute et un membre du Comité présidentiel des visites de Dana-Farber/Harvard Medical School pour l’oncologie pédiatrique. Czech est également le président du Conseil d’administration d’Alfred Angelo, Inc. Czech a reçu un baccalauréat ès sciences de la Marquette University et un MBA de l’Université Chicago Booth School of Business.

À propos de Czech Asset Management, L.P. Czech Asset Management, L.P., avec environ 4,3 milliards $ de capital engagé sous gestion et une capacité de co-investissement significative, est une société de prêts directs située à Greenwich dans le Connecticut engagée dans l’accord de prêts garantis prioritaires à taux variable négociés de gré à gré fondés sur les actifs et la trésorerie de premier ou second rang principalement pour les sociétés américaines du marché intermédiaire qui génèrent des revenus annuels de 75 à plus de 500 millions $ et un BAIIDA annuel de 7,5 à plus de 50 millions $.

SOURCE The Mikey Czech Foundation, Inc.

Nadace Mikey Czech přispěla částkou 1 milionu USD na výzkum DIPG ve výzkumném centru Dana-Farber Cancer Institute

NEW CANAAN, Connecticut, 30. března 2017 /PRNewswire/ — Nadace Mikey Czech Foundation, Inc. (dále „Nadace”), www.mikeyczech.org), která je neziskovou organizací podle odstavce 501(c)(3) amerického zákona, byla založena manžely Stephenem J. a Jennifer L. Czech za účelem financování lékařského výzkumu mozkových nádorů u dětí, oznámila příspěvek ve výši 1 000 000 USD na výzkum dětské neuroonkologie v centru Dana-Farber, kterou vede Mark W. Kieran, MD, PhD, se sídlem v Bostonu ve státě Massachusetts. Tento dar je největším individuálním příspěvkem, který byl v historii centra Dana-Farber přiznán na výzkum difuzního gliomu mozkového kmene. Darovaná částka má umožnit další výzkum a vývoj léků na léčení difuzního gliomu mozkového kmene („DIPG”), dětského mozkového nádoru, který si v roce 2008 vyžádal život Jamese Michaela „Mikeyho” Czecha ve věku 11 let.

Nádory mozkového kmene DIPG napadají hlavové nervy dětí ve věku od 3 do 16 let a ničí nervy, které zásobují oční, obličejové a polykací svaly. K příznakům patří zdvojené vidění, neschopnost úplného domykání očních víček, povisnutí jedné straně obličeje a potíže se žvýkáním a polykáním. Tento nádor napadá také čelní nebo spánkové laloky mozku, což vede k ochabování paží nebo nohou a potížím s mluvením a chůzí. S rozrůstajícím se nádorem děti zpočátku ztratí schopnost používat končetiny. Následně ztratí schopnost polykat a dýchat. Děti si navzdory zhoršenému fyzickému stavu zachovávají své mentální schopnosti a plně si uvědomují, co se s nimi děje. Doba přežití delší než 12 až 14 měsíců je neobvyklá, z toho důvodu jsou naléhavě potřebná nová řešení léčení těchto nádorů, protože v současnosti nejsou známy žádné efektivní terapie léčení DIPG.

„K aspektům potřebným k léčení DIPG patří: (a) udržitelný zdroj financování; (b) neuroonkologové světové úrovně; a (c) nejmodernější výzkumná zařízení,” uvedl Steve Czech, otec Mikeyho a předseda a spolumajitel Nadace Mikeyho Czecha. „Chceme být udržitelným zdrojem financování a jsme přesvědčeni, že Dr. Kieran, jeho kolegové a institut Dana-Farber představují to nejlepší ve své třídě s ohledem na výzkum v oblasti pediatrické neuroonkologie a nejmodernější výzkumná zařízení. Tento dar je naším druhým z řady darů, které, jak věříme, budou srovnatelné nebo vyšší a pomůžou vyhladit tuto děsivou chorobou.”

Kromě své práce v nadaci je Steve Czech vedoucím partnerem a investičním ředitelem společnosti Czech Asset Management, L.P., alternativního investičního podniku zaměřeného na úvěry v Greenwich, CT spravujícího přibližně 4,3 miliardy USD upsaného kapitálu a s významnou schopností spolufinancování. Ve snaze zajistit udržitelný zdroj financování pro výzkum DIPG pan Czech přispívá na tento výzkum procenty svých osobních příjmů.

„Finanční podpora Nadace Mikeyho Czecha je klíčová, protože nám pomůže pokračovat ve výzkumu, který má za cíl definovat molekulární změny DIPG, které byly příčinou dřívější odolnosti vůči léčbě,” uvedl Mark W. Kieran, MD, PhD, ředitel pediatrické neuroonkologie výzkumného centra Dana-Farber Cancer Institute. „Toto úsilí má již své výsledky. První státní klinické zkoušky biopsie DIPG a molekulární klasifikace s následným léčením na základě jednotlivých specifických odchylek nádorů pacientů (první testy tohoto druhu na světě) již byly dokončeny. Toto úsilí přineslo zjištění, že se DIPG vyskytuje ve třech různých variantách se specifickými molekulárními vlastnostmi, které mutují různým způsobem, některé z nich se vyskytují pouze u DIPG a nejsou známy u jiných nádorů. Institut Dana-Farber nyní vyvíjí proti těmto mutacím cílené terapie a doufá, že konečně budeme schopni významným způsobem přispět k léčení této choroby. Veškeré toto úsilí je důsledkem odhodlání pacientů, jejich rodin a nadací, včetně Nadace Mikeyho Czecha, bez kterých by toto nebylo možné.”

„DIPG je pro dětské pacienty a jejich rodiny devastující chorobou. Díky finanční podpoře nadace Mikeyho Czecha může Dr. Kieran pokračovat ve svém důležitém výzkumu a doufejme, že jednoho dne najde lék na DIPG,” uvedla Laurie H. Glimcher, MD, prezidentka a generální ředitelka výzkumného centra Dana-Farber Cancer Institute.

O Nadaci Mikeyho Czecha: The Mikey Czech Foundation, Inc. (dále „Nadace”), která je neziskovou organizací podle odstavce 501(c)(3) amerického zákona, byla založena rodinou Mikeyho za účelem financování lékařského výzkumu pediatrických mozkových nádorů, včetně difuzního gliomu mozkového kmene („DIPG”). Nádory mozkového kmene DIPG jsou extrémně ojedinělé. Celostátně je hlášeno přibližně 300 případů ročně, což bohužel v lékařské výzkumné komunitě odsouvá tuto formu nádorového onemocnění do statutu „osiřelý”, protože návratnost omezených investic do lékařského výzkumu je při léčení dětí s tímto typem nádoru z důvodu jeho malého výskytu problematická. Nadace bude v rámci tohoto výzkumu poskytovat dotace na podporu výzkumu ve zdravotnictví, vzdělávání a nákupu výzkumných zařízení v celých Spojených státech.

O difuzním gliomu mozkového kmene (DIPG): Nádory mozkového kmene napadají hlavové nervy, čímž způsobují příznaky související s nervy, které zásobují oční, obličejové a polykací svaly. K těmto příznakům patří zdvojený obraz, neschopnost úplného domykání očních víček, povisnutí na jedné straně obličeje a potíže se žvýkáním a polykáním. Tento nádor napadá také čelní nebo spánkové laloky mozku, což vede k ochabování paží nebo nohou a potížím s mluvením a chůzí. S rozrůstajícím se nádorem děti zpočátku ztratí schopnost používat končetiny. Následně ztratí schopnost polykat a dýchat a začínají se u nich projevovat změny tepové frekvence. Děti si navzdory zhoršenému fyzickému stavu zachovávají své mentální schopnosti a plně si uvědomují, co se s nimi děje.

Příznaky se obvykle rychle zhoršují, protože se nádor rychle rozrůstá. Příznaky se u pacientů dramaticky zlepšují po šesti týdnech ozařování. Problémy se bohužel obvykle vracejí po zhruba šesti měsících a rychle postupují. Doba přežití delší než 12 až 14 měsíců je neobvyklá a téměř všechny děti podlehly této chorobě během 2 až 3 let. Nová řešení léčení těchto nádorů jsou naléhavě nutná.

O výzkumném centru Dana-Farber Cancer Institute: Od dosažení první remise rakoviny díky chemoterapii v roce 1948 po vývoj nejnovějších terapií je výzkumné centrum Dana-Farber Cancer Institute jedním z předních světových center výzkumu rakoviny a jejího léčení. Je jediným centrem, které se podle žebříčků nejlepších nemocnic U.S. News a World Report’s Best Hospitals řadí mezi 4 nejlepší v oblasti léčení rakoviny jak u dospělých, tak u dětí.

Institut Dana-Farber spolupracuje na mnohých projektech snižování onkologického zatížení pomocí vědeckého výzkumu, klinické péče, vzdělávání, zainteresovaní komunity a hájení zájmů. Dana-Farber/Brigham a Onkologické centrum pro ženy nabízí nejmodernější léčbu rakoviny pro dospělé a Dana-Farber/Bostonské centrum dětské onkologie a krevních onemocnění pro děti. Dana-Farber/Harvardské onkologické centrum spojuje snahy pěti harvardských akademických lékařských center v oblasti onkologického výzkumu a dvou vysokých škol, zatímco Komunitní onkologické centrum institutu Dana-Farber zajišťuje vysokou kvalitu léčby rakoviny v komunitách mimo bostonskou lékařskou oblast Longwood.

Institut Dana-Farber udržuje rovnováhu mezi onkologickým výzkumem a péčí a věnuje veliké úsilí transformaci výsledků svých objevů do nových způsobů léčby doma a ve světě.

O Stephenu J. Czechovi: Steve Czech má za sebou více než 28 let zkušeností v oblasti úvěrů a podnikových financí. Během své kariéry také založil a vedl mnoho úvěrových fondů poskytujících přímé půjčky. Do jeho osobního portfolia patří shromažďování zdrojů, strukturalizace, úpisy, monitorování a restrukturalizace podnikových úvěrů. Před založením společnosti Czech Asset Management byl Steve zaměstnán v několika předních firmách, mezi jinými ve společnosti Morgan Stanley, Credit Suisse Group AG, Donaldson, Lufkin & Jenrette („DLJ”) a Banc of America Securities LLC. Czech a jeho rodina jsou významnými dárci a obhájci společenských problémů, které se týkají: (i) smrtelně nemocných dětí, (ii) námořních, leteckých a pozemních týmů v aktivní službě a výslužbě a jejich rodin, (iii) záchranářů (tj. příslušníků policie, hasičských jednotek a rychlé zdravotnické pomoci) a (iv) stipendií pro středoškoláky z nízkopříjmových rodin v celých Spojených státech. Czech je zakladatelem a jedním z prezidentů Nadace Mikeyho Czecha, členem národní řídicí rady nadace Navy SEAL, členem poradního výboru Chicago Booth School of Business v rámci univerzity v Chicago, čestným členem děkanské společnosti Booth School of Business v rámci univerzity v Chicago, členem prezidentského klubu a výkonného výboru rodičů Villanovské univerzity, členem Asklepionovské společnosti onkologického institutu Dana-Farber a členem prezidentského hostujícího výboru pro pediatrickou onkologii institutu Dana-Farber. Czech je také předsedou rady společnosti Alfred Angelo, Inc. Marquettská univerzita udělila Czechovi titul B.S. a Booth School of Business při univerzitě v Chicago mu udělila titul MBA.

O společnosti Czech Asset Management, L.P. Czech Asset Management, L.P. spravuje kapitál ve výši okolo 4,3 miliardy USD a kromě toho vlastní značné finanční prostředky na spolufinancování. Společnost, která nabízí přímé půjčky, sídlí v Greenwich ve státě Connecticut a jejím hlavním zaměřením jsou soukromě vyjednávané vysoce zabezpečené úvěry s pohyblivým úrokem, které jsou zajištěny aktivy a prvním a druhým záložním právem na hotovost a jsou poskytovány zejména středně velkým podnikům v USA, které ročně vytvářejí výnos od 75 do 500 a více milionů USD a jejichž úroveň EBITDA se ročně pohybuje mezi 7,5 milionu USD a 50 miliony USD.

SOURCE The Mikey Czech Foundation, Inc.